focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 107.60
Bid: 107.60
Ask: 108.40
Change: -2.60 (-2.36%)
Spread: 0.80 (0.743%)
Open: 109.00
High: 109.00
Low: 106.60
Prev. Close: 110.20
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Stocks set lower after US Fed decision, ahead of ECB

Thu, 15th Jun 2023 07:55

(Alliance News) - Stocks in London were set to open lower on Thursday, after the US Federal Reserve paused its interest rate hikes but indicated that more will follow this year.

The US central bank left the federal funds rate range unchanged at a range of 5.00% to 5.25%.

Speaking to reporters after the decision, Fed Chair Jerome Powell said nearly all committee participants view some further hikes this year as "appropriate".

Chris Beauchamp, chief market analyst at IG, said "any lingering hope" of a rate cut this year from the Fed now seems to have gone following this meeting.

In the wake of the announcement, Wall Street ended mixed, but the dollar was stronger.

With the Fed decision made, the European Central Bank is up next. The ECB will announce its interest rate decision on Thursday at 1315 BST. A press conference with President Christine Lagarde will follow half an hour later.

In contrast to the US central bank, another 25 basis point hike by the ECB is see as a done deal by markets.

In early UK corporate news, distribution services firm Halma boasted a record annual revenue figure but lower profit. Online fashion retailer Asos said it had "restored profitability".

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 17.34 points, or 0.2%, at 7,585.40

----------

Hang Seng: up 1.6% at 19,715.34

Nikkei 225: closed down 0.1% at 33,485.49

S&P/ASX 200: closed up 0.2% at 7,175.30

----------

DJIA: closed down 232.79 points, or 0.7%, at 33,979.33

S&P 500: closed up 0.1% at 4,372.59

Nasdaq Composite: closed up 0.4% at 13,626.48

----------

EUR: lower at USD1.0818 (USD1.0850)

GBP: lower at USD1.2651 (USD1.2694)

USD: higher at JPY141.30 (JPY139.37)

Gold: lower at USD1,935.49 per ounce (USD1,957.97)

(Brent): lower at USD73.52 a barrel (USD74.27)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

UK BoE Deputy Governor Jon Cunliffe speaks at Politico Global Tech summit

11:00 CEST EU foreign trade

14:15 CEST EU interest rate announcement

08:30 EDT US import and export price index

08:30 EDT US Philadelphia Fed business outlook survey

08:30 EDT US unemployment insurance weekly claims report

09:15 EDT US industrial production

16:30 EDT US foreign central bank holdings

16:30 EDT US federal discount window borrowings

----------

China reported a series of weak economic indicators, with youth unemployment hitting a record high for the second consecutive month as the economy's post-Covid growth spurt fades. The unemployment rate for Chinese between the ages of 16 and 24 rose to 20.8%, up from what was already a record 20.4% in April, the National Bureau of Statistics said. Overall urban unemployment remained at 5.2%, the NBS said in a statement. Meanwhile, industrial production rose 3.5% in May, down from 5.6% a month earlier, as factories gradually returned to full capacity. Retail sales, the main indicator of household consumption, rose by 12.7% on-year compared with 18.4% a month earlier.

----------

Amid the weak economic readings, China's central bank cut a key interest rate and injected USD33 billion into financial market. The medium-term lending facility rate – the interest for one-year loans to financial institutions – was lowered 10 basis points to 2.65%, the People's Bank of China said in a statement. The PBOC also said it was offering USD33 billion of funds to banks through the medium-term lending facility, "to maintain reasonable and sufficient liquidity in the banking system". The bank also announced a surprise cut in a short-term interest rate this week, which analysts said reflected growing concern about the state of the economy among Chinese policymakers.

----------

A strike by junior doctors in England will continue on Thursday as new figures showed that more than half a million appointments and procedures have been postponed due to industrial action since December. Members of the British Medical Association will mount picket lines outside hospitals across the country for the second of a three-day walkout in a long-running row over pay. The action is expected to lead to tens of thousands more appointments and procedures being delayed. The dispute remains deadlocked, with no talks planned amid a standoff between the BMA and government. The BMA has urged Prime Minister Rishi Sunak to get involved in talks, but it was made clear he is not going to intervene.

----------

BROKER RATING CHANGES

----------

Goldman Sachs cuts Diageo to 'neutral' (buy) - price target 3,700 (4,500) pence

----------

Berstein starts AB Foods with 'outperform'

----------

Berenberg starts Adriatic Metals with 'buy' - price target 280 pence

----------

COMPANIES - FTSE 100

----------

Bunzl said it expects to deliver another "resilient" performance in the first half of 2023, with revenue expected to be up between 4% and 5% year-on-year at actual exchange rates, or 1% at constant exchange rates. The distribution services company said that, in 2023 as whole, revenue is expected to be "slightly" higher than in 2022. Bunzl also announced it has entered an agreement to acquire EHM, a distributor of personal protective equipment products in the UK. The company said the acquisition would be complementary to its existing safety business. The financial details were not disclosed.

----------

Halma boasted a record annual revenue figure in the financial year that ended March 31 but lower profit. The safety equipment manufacturer posted pretax profit of GBP291.5 million, down from GBP304.4 million the year prior. Halma said the drop in profitability reflected the non-recurrence of a GBP34.0 million gain on a disposal in the year prior. Excluding this gain, pretax profit was up 8% year-on-year, it said. Revenue from continuing operations totalled GBP1.85 billion, up from GBP1.53 billion. Chief Executive Marc Ronchetti said: "We have made a positive start to the new financial year. We have a strong order book, and order intake in the year to date is broadly in line with revenue and ahead of the comparable period last year. Based on current market conditions, we expect to deliver good organic constant currency revenue growth in the year ahead, and return on sales to increase to approximately 20%."

----------

COMPANIES - FTSE 250

----------

Asos said it returned to profitability with its 'P3' adjusted earnings before interest and tax in the three months ended May 31, despite a drop in revenue. P3 adjusted Ebit was improved by more than GBP20 million year-on-year, putting the online fashion retailer on-track to deliver adjusted Ebit guidance of GBP40 million to GBP60 million in the second half of its financial year. Revenue fell 14% year-on-year, as expected by the company. Chief Executive Jose Antonio Ramos Calamonte said: "I am confident in the direction we are going, we have restored profitability in the period and made good progress in clearing through our inventory to generate cash. We retain ample balance sheet flexibility and reiterate our expectations for improved profitability, cash generation and reduction in net debt in H2 FY23 and beyond."

----------

Syncona reported a lower net asset value per share at the end of March amid a "challenging" backdrop for the biotechnology companies. The healthcare investor reported a net asset value per share of 186.5 pence as at March 31, down from 194.4p at the same time a year prior. Its total NAV return in the financial year that ended March 31 was negative 4.1%, compared to positive 0.3% the year prior. The company's life science portfolio is valued at GBP604.6 million as of March 31. Syncona said its performance had been driven by the continued share price declines of its listed holdings, which it said partially reflected the wider market backdrop for biotech companies and the write down of its valuation of SwanBio. Syncona has written down its holding in SwanBio to GBP58.2 million, a GBP51.0 million decline in value during the year.

----------

OTHER COMPANIES

----------

Kew Soda, also known as WE Soda, late Wednesday cancelled plans to float on the London Stock Exchange, with the soda ash producer explaining that UK investors are cautious about the initial public offering market. Chief Executive Alasdair Warren said: "Since our intention to float announcement some weeks ago, we had been encouraged by the breadth of investor engagement globally and the subsequent interest from prospective investors in our IPO. "Despite this, the reality is that investors, particularly in the UK, remain extremely cautious about the IPO market and this extreme investor caution in London meant that we were unable to arrive at a valuation that we believe reflects our unique financial and operating characteristics." WE Soda is the world's largest natural soda ash producer. It is based in London with production facilities in Turkey.

----------

GB Group said it was hurt by "unexpectedly deep post-pandemic corrections" in some of its end markets in the financial year that ended March 31, as it swung to an annual loss. The digital location and identity services provider explained that the corrections were largely felt in the internet economy, notably by cryptocurrency and fintech customers in its Identity business in the Americas. GB Group reported a loss of GBP119.8 million, swinging from a profit of GBP15.3 million the year prior. Revenue totalled GBP278.8 million, up from GBP242.5 million. Chief Executive Chris Clark said: "Looking ahead to FY24, since our update in February, there has been no material change in market conditions. Uncertainty remains; however, we still expect some gradual revenue acceleration in the latter part of the year. The board is confident that GBG will deliver its FY24 profit expectations assisted by a group-wide focus on efficiency. "

----------

Origin Enterprises said its markets in the nine months ended April 30 have been "significant" price and volume volatility, requiring "close management". The agronomy services firm said revenue in the period was up 9.3% against the year prior at EUR1.92 billion despite third quarter revenue falling 16% year-on-year. It explained that its performance in the third quarter quarter of its financial year was impacted by cautious on farm sentiment and poor northern hemisphere in-field conditions delaying key crop input applications. However, Origin noted that weather conditions and demand have improved into its fourth quarter. It expects adjusted diluted earnings per share for the full-year between 50.0 euro cents to 53.0 cents.

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
22 Nov 2023 14:30

IN BRIEF: Syncona agrees to buyout deal with Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.

Read more
16 Nov 2023 10:34

Syncona reports declining asset value as investment head steps down

(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".

Read more
16 Nov 2023 08:44

Syncona net asset value falls, co-founder steps down

(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.

Read more
14 Nov 2023 11:29

IN BRIEF: Syncona notes investee company's quarterly loss

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to USD16.7 million in the third quarter of 2023 from USD12.4 million the year before, as operating expenses rose 19% to USD19.1 million from USD16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles.

Read more
9 Nov 2023 15:44

UK earnings, trading statements calendar - next 7 days

Friday 10 November 
Allianz Technology Trust PLCQ3 Results
Wheaton Precious Metals CorpQ3 Results
Monday 13 November 
Bank of Cyprus Holdings PLCQ3 Results
British Land Co PLCHalf Year Results
Kainos Group PLCHalf Year Results
Team Internet Group PLCQ3 Results
Tuesday 14 November 
ActiveOps PLCHalf Year Results
Babcock International Group PLCHalf Year Results
Bank of Georgia Group PLCQ3 Results
Castings PLCHalf Year Results
ConvaTec Group PLCTrading Statement
DCC PLCHalf Year Results
Forterra PLCHalf Year Results
Gear4Music PLCHalf Year Results
Genel Energy PLCTrading Statement
HydrogenOne Capital Growth PLCQ3 Results
Hill & Smith PLCTrading Statement
Imperial Brands PLCFull Year Results
Informa PLCTrading Statement
Land Securities Group PLCHalf Year Results
Oxford Instruments PLCHalf Year Results
Picton Property Income LtdHalf Year Results
Renalytix PLCQ1 Results
Vesuvius PLCTrading Statement
Vodafone Group PLCHalf Year Results
Wise PLCHalf Year Results
Wednesday 15 November 
Diversified Energy Co PLCTrading Statement
Experian PLCHalf Year Results
Fuller, Smith & Turner PLCHalf Year Results
Genuit Group PLCTrading Statement
Intermediate Capital Group PLCHalf Year Results
Ninety One PLC and LtdHalf Year Results
Renold PLCHalf Year Results
SSE PLCHalf Year Results
Synthomer PLCTrading Statement
Tracsis PLCFull Year Results
Tullow Oil PLCTrading Statement
Warehouse REIT PLCHalf Year Results
Thursday 16 November 
Assura PLCHalf Year Results
Atalaya Mining PLCQ3 Results
Aviva PLCTrading Statement
Burberry Group PLCHalf Year Results
Close Brothers Group PLCTrading Statement
CMC Markets PLCHalf Year Results
Crest Nicholson Holdings PLCTrading Statement
Halma PLCHalf Year Results
Great Portland Estates PLCHalf Year Results
Kier Group PLCTrading Statement
International Distributions Services PLCHalf Year Results
Investec PLC and LtdHalf Year Results
Liontrust Asset Management PLCHalf Year Results
Manolete Partners PLCHalf Year Results
Melrose Industries PLCTrading Statement
Norcros PLCHalf Year Results
Premier Foods PLCHalf Year Results
Qinetiq Group PLCHalf Year Results
Spirax-Sarco Engineering PLCTrading Statement
Syncona LtdHalf Year Results
Tatton Asset Management PLCHalf Year Results
Tyman PLCTrading Statement
United Utlities Group PLCHalf Year Results
Young & Co's Brewery PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Nov 2023 11:51

TRADING UPDATES: Augmentum Fintech makes further investment in Tide

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:

Read more
18 Oct 2023 12:01

IN BRIEF: Syncona announces takeover offer for Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Says Syncona Investment Management Ltd has submitted a non-binding proposal to acquire the entire remaining share capital of Freeline Therapeutic Holdings PLC. Offers upfront cash consideration of USD5.00 per American depository share, representing a 20% premium over the USD4.16 volume weighted average price from October 4 to October 16. Syncona currently owns around 57.9% of shares in Stevenage, England-based Freeline, which it co-founded in 2015. Freeline aims to develop gene therapies to treat chronic diseases, most notably its potentially "transformative" FLT201 programme to treat Gaucher disease.

Read more
4 Oct 2023 14:28

Syncona says Freeline and SwanBio clinical trails make progress

(Alliance News) - Syncona Ltd on Wednesday said its portfolio company Freeline Therapeutics Holdings PLC has received positive initial safety, tolerability and enzyme activity data from its FLT201 trial for the treatment of Gaucher disease.

Read more
29 Sep 2023 09:51

IN BRIEF: Syncona launches GBP40 million share buyback programme

Syncona Ltd - London-based investor in healthcare companies - Launches share buyback programme worth up to GBP40.0 million, to be conducted by Numis Securities Ltd. Says core focus remains on allocating capital to portfolio companies' assets. However the buyback is necessary due to Syncona's shares currently trading at a discount to net asset value, which was 184.6 pence per share at June 30. Says buyback will not affect investments into clinical stage assets planned for the next 24 months. Company expects that capital deployment into portfolio and pipeline will total between GBP150 million and GBP200 million for the year ending March 31, in line with prior guidance. Chair Melanie Gee says Syncona "has a high level of confidence in our portfolio and its valuation".

Read more
11 Sep 2023 15:42

Syncona shares slump as Novartis ends eye treatment development

(Sharecast News) - Syncona shares fell as the UK healthcare investment firm said Novartis had stopped the development of experimental eye treatment, GT005, resulting in milestone payments write-off of £54.5m for Gyroscope Holdings in which Syncona once held a 54% stake.

Read more
11 Sep 2023 09:51

Syncona suffers negative valuation hit as Novartis discontinues GT005

(Alliance News) - Syncona Ltd on Monday said it has been informed by Swiss-American pharmaceutical company Novartis AG that the development of eye treatment, GT005, for geographic atrophy secondary to dry age-related macular degeneration will be discontinued.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
15 Aug 2023 13:56

IN BRIEF: Syncona notes clinical progress of portfolio firm Freeline

Syncona Ltd - London-based healthcare investor - Notes second quarter results announcement from its Nasdaq-listed portfolio company Freeline Therapeutics Holdings PLC. Says the key highlights include Freeline completing the dosing in the first dose cohort of the phase 1/2 trial of FLT201 in Gaucher disease, following dosing of the second patient. Says initial clinical data from the FLT201 trial is expected in the second half of 2023. Also says Freeline has a cash position of USD38.8 million at June 30 compared to USD55.4 million on March 31, which Freeline expects will enable the company to fund its planned operations into the second quarter of 2024. Freeline says net income in the three months that ended June 30 narrowed to USD14.8 million from USD51.1 million a year earlier.

Read more
10 Aug 2023 09:33

IN BRIEF: Syncona says net asset value slips 1% in first quarter

Syncona Ltd - London-based healthcare investor - Net asset value at June 30 is 184.6 pence per share, down 1.0% from 186.5p on March 31. NAV total return also was negative 1.0% for the recent three months, Syncona's financial first quarter. Notes performance was hurt by "negative foreign exchange movements" across its life science portfolio. This is valued at GBP628.7 million on June 30, up 4.0% from GBP604.6 million on March 31.

Read more
10 Aug 2023 08:34

Syncona reports slight dip in net assets

(Sharecast News) - Healthcare investor Syncona reported a slight dip in net assets in its quarterly update on Thursday, to £1.24bn, down from £1.26bn at the end of March.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.